Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Atorvastatin is the active ingredient of these drugs:
Lithuania
Cyprus
Italy
Lithuania
Brazil
Hong Kong
Singapore
Brazil
Singapore
Austria
Finland
Lithuania
Germany Hong Kong Italy Lithuania Poland
Hong Kong
Brazil
Hong Kong
Austria
Singapore
Cyprus
Australia
Austria
Poland
Austria
Brazil Poland
Tunisia
Austria
Singapore
Poland
Poland
Hong Kong
Poland
Tunisia
Poland
Singapore
Singapore
Hong Kong
Poland
Austria
Hong Kong
Spain
Hong Kong
Tunisia
Brazil
Brazil
Poland
Cyprus
Hong Kong
Singapore
Singapore
Hong Kong
Italy
Brazil
Cyprus Poland
Tunisia
Poland
Hong Kong
Hong Kong
Hong Kong
Hong Kong
Brazil
Hong Kong
Finland Hong Kong
Brazil
Australia Brazil Canada Cyprus Finland
Hong Kong
Hong Kong
Hong Kong
Brazil
Lithuania
Australia New Zealand
Brazil
Italy
Lithuania
Poland
Italy
Finland
Hong Kong
Spain
Italy
Austria Germany Lithuania Poland
Tunisia
Poland
Hong Kong
France Tunisia
Tunisia
Italy
Spain
Cyprus Lithuania Poland
Italy
Poland Singapore
Lithuania
Italy
Australia
Hong Kong Singapore
Brazil
Italy
Italy
Australia
Poland Singapore
Hong Kong
Brazil
Hong Kong
Hong Kong
New Zealand Spain
Atorvastatin is also found within below combination drugs:
AMLATOR , AMLOSATIN , ANCILLEG , ASTUCOR , ATORDAPIN , ATORIMIB , ATORVALAN COMP , ATOZET , CADIVAST , CADUET , CODUWON , EUVASCOR , EXTROTAN , EZEATO , EZETAST , EZEVAST , LIPERCOSYL , LIPERTANCE , LIPTA , LIPTRUZET , MIZETAM , ORVATEZ , PARVAXOR , RESELIP , TACERNOL , TORVAZIN PLUS , TORZELIP , TRINOMIA , TRIVERAM , TULIP COMBO , ZENTASTA
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):